This microburst learning, enduring dialogue between two leading experts will focus on improving clinicians knowledge and competence in the treatment personalization with emerging novel TKI options in frontline therapy of CP-CML and care strategies for patients with newly diagnosed CP-CML. As a result of this educational activity, learners should be better able to: 1. Identify the clinical rationale for using emerging novel TKIs for newly diagnosed CPCML; 2. Discuss the clinical implications of the latest data for emerging first-line novel TKIs in CP-CML; and 3. Outline potential considerations to optimize outcomes for newly diagnosed patients with CP-CML on first-line TKIs. Downloadable slides are available for learners to use in clinical practice.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https:// www.answersincme.com/MNK
- Start Date: 2024-12-27 06:00:00
- End Date: 2024-12-27 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 163564.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all